Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

Verastem Oncology (Nasdaq: VSTM) will report first quarter 2026 financial results and host a conference call and webcast on Thursday, May 7, 2026 at 4:30 PM ET.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET.

A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI^® FAKZYNJA^® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423119779/en/

For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com

Source: Verastem Oncology

Key Terms

ras/mapk pathway-driven cancers medical

A group of cancers driven by harmful changes in the RAS/MAPK signaling chain, a cellular “instruction line” that tells cells when to grow and divide; mutations can jam that signal in the “on” position, like a stuck gas pedal. Investors care because these cancers create demand for drugs, tests and combinations that target the faulty signal, shaping clinical trial risk, regulatory timelines and potential market size for therapies.